International Position Statement on Use of Human Albumin for Liver Cirrhosis-related Complications

Dear Friends and Investigators,

Thank you very much for your participation into the final advisory meeting of "International Position Statement on Use of Human Albumin Infusion for Liver Cirrhosis-related Complications (2022)".

The final voting has been prepared. It should be completed before December 4. By the way, the target journal will be also collected. Additionally, once you complete the online questionnaire, please click the Chinese-language button “ ”, which means “Submit” in English, at the bottom of the online questionnaire.

After the voting, I will contact with the editor of a preferred target journal and then format the manuscript for your final approval.

Looking forward to your response at your earliest convenience.

Yours sincerely,

Dr. Xingshun Qi
On the behalf of Liver Cirrhosis-related Complications - International Special Interest Group
*
1.
Your name
*
2.
Country
*
3.
Position statement 1. HA infusion should be used for the differential diagnosis of HRS.
Strongly agree (5 points)
Agree (4 points)
Neither agree nor disagree (3 points)
Disagree (2 points)
Strongly disagree (1 point)
Don't konw
*
4.
Position statement 2. HA infusion should be used for the management of HRS.
Strongly agree (5 points)
Agree (4 points)
Neither agree nor disagree (3 points)
Disagree (2 points)
Strongly disagree (1 point)
Don't konw
*
5.
Position statement 3. HA infusion should be used for the prevention of PPCD in patients with liver cirrhosis and ascites undergoing LVP (>5 L). HA infusion could be considered in cirrhotic patients with acute on chronic liver failure (ACLF)/AKI undergoing paracentesis of <5 L.
Strongly agree (5 points)
Agree (4 points)
Neither agree nor disagree (3 points)
Disagree (2 points)
Strongly disagree (1 point)
Don't konw
*
6.
Position statement 4. In the setting where budget and logistical issues can be resolved, long-term regular HA infusion can be used to improve ascites, prevent other complications of liver cirrhosis, and prolong survival in patients with uncomplicated ascites requiring diuretics.
Strongly agree (5 points)
Agree (4 points)
Neither agree nor disagree (3 points)
Disagree (2 points)
Strongly disagree (1 point)
Don't know
*
7.
Position statement 5. HA infusion should be used to prevent AKI and improve survival in cirrhotic patients with SBP, particularly those with baseline serum bilirubin ≥4 mg/dL or serum creatinine ≥1 mg/dL.
Strongly agree (5 points)
Agree (4 points)
Neither agree nor disagree (3 points)
Disagree (2 points)
Strongly disagree (1 point)
Don't konw
*
8.
Position statement 6. HA infusion does not prevent renal impairment or improve survival in patients with cirrhosis affected by non-SBP infections other than septic shock.
Strongly agree (5 points)
Agree (4 points)
Neither agree nor disagree (3 points)
Disagree (2 points)
Strongly disagree (1 point)
Don't konw
*
9.
Position statement 7. HA infusion may be considered for the management of overt HE, especially in patients with liver cirrhosis and hypoalbuminemia.
Strongly agree (5 points)
Agree (4 points)
Neither agree nor disagree (3 points)
Disagree (2 points)
Strongly disagree (1 point)
Don't know
*
10.
Position statement 8. HA infusion may be considered to improve and prevent hyponatremia in cirrhotic patients, but its effect needs to be further explored.
Strongly agree (5 points)
Agree (4 points)
Neither agree nor disagree (3 points)
Disagree (2 points)
Strongly disagree (1 point)
Don't konw
*
11.
Position statement 9. More data are warranted to evaluate the use of HA to attenuate muscle cramps in patients with liver cirrhosis.
Strongly agree (5 points)
Agree (4 points)
Neither agree nor disagree (3 points)
Disagree (2 points)
Strongly disagree (1 point)
Don't know
*
12.
Position statement 10. HA may be considered for the management of cirrhotic patients with septic shock.
Strongly agree (5 points)
Agree (4 points)
Neither agree nor disagree (3 points)
Disagree (2 points)
Strongly disagree (1 point)
Don't know
*
13.
Position statement 11. Short-term HA infusion in general patients with acute decompensation of cirrhosis may not be beneficial. Further validation should be considered.
Strongly agree (5 points)
Agree (4 points)
Neither agree nor disagree (3 points)
Disagree (2 points)
Strongly disagree (1 point)
Don't know
*
14.
Position statement 12. HA infusion is generally safe, but may induce the development of pulmonary edema and severe allergic reactions.
Strongly agree (5 points)
Agree (4 points)
Neither agree nor disagree (3 points)
Disagree (2 points)
Strongly disagree (1 point)
Don't know
*
15.
Target journal【多选题】
You can select one or two journals.
Lancet Gastroenterology & Hepatology
Journal of Hepatology
GUT
Nature Reviews Gastroenterology & Hepatology
Others
问卷星提供技术支持
举报